Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children

Bindu Parachalil Gopalan, Reena R. D’Souza, Niharika Rajnala, Karthika Arumugam, Mary Dias, Udaykumar Ranga, Anita Shet

Research output: Contribution to journalArticle

Abstract

Using cell-associated DNA and cell-free RNA of human immunodeficiency virus type-1 (HIV-1), we investigated the role of drug-resistant viral variants that emerged during early antiretroviral therapy (ART) in determining virological outcome. This case-control study compared virologic nonresponder children (two viral loads [VLs] ≥ 200 copies/mL within 2 years of ART) and responder children (two VLs < 200 copies/mL after six months of ART) infected with HIV-1 initiated on nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART. The partial reverse-transcriptase gene of HIV-1 in cell-associated DNA was genotyped using next-generation sequencing (NGS; Illumina; threshold 0.5%; at baseline and month six of ART) and in cell-free RNA (concurrently and at virological failure; VL > 1000 copies/mL at ≥ 12 months of ART) using the Sanger method. Among 30 nonresponders and 37 responders, baseline differences were insignificant while adherence, VL, and drug resistance mutations (DRMs) observed at month six differed significantly (P ≥ 0.05). At month six, NGS estimated a higher number of DRMs compared with Sanger (50% vs 33%; P = 0.001). Among the nonresponders carrying a resistant virus (86.6%) at virological failure, 26% harbored clinically relevant low-frequency DRMs in the cell-associated DNA at month six (0.5%-20%; K103N, G190A, Y181C, and M184I). Plasma VL of > 3 log 10 copies/mL (AOR, 30.4; 95% CI, 3.3-281; P = 0.003) and treatment-relevant DRMs detected in the cell-associated DNA at month six (AOR, 24.2; 95% CI, 2.6-221; P = 0.005) were independently associated with increased risk for early virological failure. Our findings suggest that treatment-relevant DRMs acquired in cell-associated DNA during the first six months of ART can predict virological failure in children initiated on NNRTI-based ART.

Original languageEnglish (US)
JournalJournal of Medical Virology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Satellite Viruses
Secondary Prevention
Drug Resistance
HIV-1
Viral Load
DNA
Mutation
Therapeutics
Viral Drug Resistance
Case-Control Studies
RNA
Viruses
Pharmaceutical Preparations

Keywords

  • cell-associated DNA
  • cell-free RNA
  • children
  • drug-resistance mutations
  • HIV-1
  • next-generation sequencing
  • nonresponder
  • responder
  • subtype C

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children. / Gopalan, Bindu Parachalil; D’Souza, Reena R.; Rajnala, Niharika; Arumugam, Karthika; Dias, Mary; Ranga, Udaykumar; Shet, Anita.

In: Journal of Medical Virology, 01.01.2019.

Research output: Contribution to journalArticle

Gopalan, Bindu Parachalil ; D’Souza, Reena R. ; Rajnala, Niharika ; Arumugam, Karthika ; Dias, Mary ; Ranga, Udaykumar ; Shet, Anita. / Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children. In: Journal of Medical Virology. 2019.
@article{3a647e9ee148440386c8aaa427c38dc1,
title = "Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children",
abstract = "Using cell-associated DNA and cell-free RNA of human immunodeficiency virus type-1 (HIV-1), we investigated the role of drug-resistant viral variants that emerged during early antiretroviral therapy (ART) in determining virological outcome. This case-control study compared virologic nonresponder children (two viral loads [VLs] ≥ 200 copies/mL within 2 years of ART) and responder children (two VLs < 200 copies/mL after six months of ART) infected with HIV-1 initiated on nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART. The partial reverse-transcriptase gene of HIV-1 in cell-associated DNA was genotyped using next-generation sequencing (NGS; Illumina; threshold 0.5{\%}; at baseline and month six of ART) and in cell-free RNA (concurrently and at virological failure; VL > 1000 copies/mL at ≥ 12 months of ART) using the Sanger method. Among 30 nonresponders and 37 responders, baseline differences were insignificant while adherence, VL, and drug resistance mutations (DRMs) observed at month six differed significantly (P ≥ 0.05). At month six, NGS estimated a higher number of DRMs compared with Sanger (50{\%} vs 33{\%}; P = 0.001). Among the nonresponders carrying a resistant virus (86.6{\%}) at virological failure, 26{\%} harbored clinically relevant low-frequency DRMs in the cell-associated DNA at month six (0.5{\%}-20{\%}; K103N, G190A, Y181C, and M184I). Plasma VL of > 3 log 10 copies/mL (AOR, 30.4; 95{\%} CI, 3.3-281; P = 0.003) and treatment-relevant DRMs detected in the cell-associated DNA at month six (AOR, 24.2; 95{\%} CI, 2.6-221; P = 0.005) were independently associated with increased risk for early virological failure. Our findings suggest that treatment-relevant DRMs acquired in cell-associated DNA during the first six months of ART can predict virological failure in children initiated on NNRTI-based ART.",
keywords = "cell-associated DNA, cell-free RNA, children, drug-resistance mutations, HIV-1, next-generation sequencing, nonresponder, responder, subtype C",
author = "Gopalan, {Bindu Parachalil} and D’Souza, {Reena R.} and Niharika Rajnala and Karthika Arumugam and Mary Dias and Udaykumar Ranga and Anita Shet",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jmv.25413",
language = "English (US)",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Viral evolution in the cell-associated HIV-1 DNA during early ART can lead to drug resistance and virological failure in children

AU - Gopalan, Bindu Parachalil

AU - D’Souza, Reena R.

AU - Rajnala, Niharika

AU - Arumugam, Karthika

AU - Dias, Mary

AU - Ranga, Udaykumar

AU - Shet, Anita

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Using cell-associated DNA and cell-free RNA of human immunodeficiency virus type-1 (HIV-1), we investigated the role of drug-resistant viral variants that emerged during early antiretroviral therapy (ART) in determining virological outcome. This case-control study compared virologic nonresponder children (two viral loads [VLs] ≥ 200 copies/mL within 2 years of ART) and responder children (two VLs < 200 copies/mL after six months of ART) infected with HIV-1 initiated on nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART. The partial reverse-transcriptase gene of HIV-1 in cell-associated DNA was genotyped using next-generation sequencing (NGS; Illumina; threshold 0.5%; at baseline and month six of ART) and in cell-free RNA (concurrently and at virological failure; VL > 1000 copies/mL at ≥ 12 months of ART) using the Sanger method. Among 30 nonresponders and 37 responders, baseline differences were insignificant while adherence, VL, and drug resistance mutations (DRMs) observed at month six differed significantly (P ≥ 0.05). At month six, NGS estimated a higher number of DRMs compared with Sanger (50% vs 33%; P = 0.001). Among the nonresponders carrying a resistant virus (86.6%) at virological failure, 26% harbored clinically relevant low-frequency DRMs in the cell-associated DNA at month six (0.5%-20%; K103N, G190A, Y181C, and M184I). Plasma VL of > 3 log 10 copies/mL (AOR, 30.4; 95% CI, 3.3-281; P = 0.003) and treatment-relevant DRMs detected in the cell-associated DNA at month six (AOR, 24.2; 95% CI, 2.6-221; P = 0.005) were independently associated with increased risk for early virological failure. Our findings suggest that treatment-relevant DRMs acquired in cell-associated DNA during the first six months of ART can predict virological failure in children initiated on NNRTI-based ART.

AB - Using cell-associated DNA and cell-free RNA of human immunodeficiency virus type-1 (HIV-1), we investigated the role of drug-resistant viral variants that emerged during early antiretroviral therapy (ART) in determining virological outcome. This case-control study compared virologic nonresponder children (two viral loads [VLs] ≥ 200 copies/mL within 2 years of ART) and responder children (two VLs < 200 copies/mL after six months of ART) infected with HIV-1 initiated on nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART. The partial reverse-transcriptase gene of HIV-1 in cell-associated DNA was genotyped using next-generation sequencing (NGS; Illumina; threshold 0.5%; at baseline and month six of ART) and in cell-free RNA (concurrently and at virological failure; VL > 1000 copies/mL at ≥ 12 months of ART) using the Sanger method. Among 30 nonresponders and 37 responders, baseline differences were insignificant while adherence, VL, and drug resistance mutations (DRMs) observed at month six differed significantly (P ≥ 0.05). At month six, NGS estimated a higher number of DRMs compared with Sanger (50% vs 33%; P = 0.001). Among the nonresponders carrying a resistant virus (86.6%) at virological failure, 26% harbored clinically relevant low-frequency DRMs in the cell-associated DNA at month six (0.5%-20%; K103N, G190A, Y181C, and M184I). Plasma VL of > 3 log 10 copies/mL (AOR, 30.4; 95% CI, 3.3-281; P = 0.003) and treatment-relevant DRMs detected in the cell-associated DNA at month six (AOR, 24.2; 95% CI, 2.6-221; P = 0.005) were independently associated with increased risk for early virological failure. Our findings suggest that treatment-relevant DRMs acquired in cell-associated DNA during the first six months of ART can predict virological failure in children initiated on NNRTI-based ART.

KW - cell-associated DNA

KW - cell-free RNA

KW - children

KW - drug-resistance mutations

KW - HIV-1

KW - next-generation sequencing

KW - nonresponder

KW - responder

KW - subtype C

UR - http://www.scopus.com/inward/record.url?scp=85061247983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061247983&partnerID=8YFLogxK

U2 - 10.1002/jmv.25413

DO - 10.1002/jmv.25413

M3 - Article

C2 - 30695102

AN - SCOPUS:85061247983

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

ER -